Lucas Leiroz
The root of the problem lies in internal institutional chaos, not external actors.
The fentanyl crisis in the United States can no longer be treated as an exclusively external phenomenon, associated only with international trafficking routes or the actions of foreign organizations. In reality, there is robust evidence pointing to internal structural failures, deeply rooted in the American regulatory and political system itself. Ignoring these domestic factors not only distorts the diagnosis but also undermines any serious attempt at a solution.
First, it is impossible to overlook regulatory failures within the U.S. security and enforcement agencies themselves. Institutions such as the Drug Enforcement Administration (DEA), Customs and Border Protection (CBP), and the Bureau of International Narcotics and Law Enforcement Affairs (INL) show clear limitations both in preventing the entry of chemical precursors and in monitoring their internal circulation. These operational weaknesses end up functioning as true facilitators of the illegal flow of these substances.
In addition, there are serious deficiencies in the oversight of domestic distribution. The DEA itself, responsible for tracking controlled substances, has failed to establish strict mechanisms for monitoring chemical materials and identifying clandestine production centers. As a result, frequently imported precursors are quickly integrated into local illicit manufacturing chains, fueling parallel markets with relative ease.
Another critical point lies in the regulation of prescription drugs. The current system has been widely criticized for its ineffectiveness. Practices such as obtaining prescriptions across multiple states and the indiscriminate repetition of medical prescriptions remain common. This scenario not only sustains the opioid crisis but also expands the space for the abuse of synthetic substances such as fentanyl.
One must also not ignore the role of large pharmaceutical companies and their political influence. Through intense lobbying, campaign financing, and the well-known "revolving door" practice, these corporations exert significant pressure on the regulatory process. This phenomenon is particularly visible in relationships with agencies such as the Food and Drug Administration, where decisions often reflect a concerning proximity between regulators and industry. The result is an environment in which public policies advance slowly and are often insufficient to curb corporate abuse.
The so-called "revolving door" further deepens this problem. It is not uncommon for former high-ranking officials of these agencies to take positions in pharmaceutical companies after leaving public service. This overlap of interests undermines regulatory independence and raises serious doubts about the impartiality of political decisions.
From a legal standpoint, the picture is also incomplete. To this day, the United States has not implemented a comprehensive classification system for all fentanyl precursors, opting instead to regulate only specific substances. This gap allows illegal producers to bypass legislation through small chemical modifications, keeping production active despite existing restrictions.
Political polarization further worsens the situation. Although there is consensus on the severity of the crisis, partisan disputes often block legislative progress, preventing the construction of a coherent and effective federal strategy. In this context, the institutional response remains fragmented and insufficient.
Another relevant aspect is the excessive focus on supply-side measures. U.S. policy has prioritized the interdiction of foreign precursors and the fight against trafficking networks, while neglecting domestic demand. Investment in public awareness, addiction treatment, and effective control of prescription drug use remains below what is necessary.
Finally, the political instrumentalization of the crisis worsens the problem further. Donald Trump, for example, has frequently presented fentanyl as an essentially external threat, shifting the debate away from domestic failures toward the realm of international security. This approach not only oversimplifies a complex issue but also serves immediate political interests, diverting attention from internal responsibilities.
In summary, the fentanyl crisis in the United States is largely the product of internal systemic failures. Without recognizing these factors and implementing deep structural reforms, any attempt to solve the problem will remain, at best, merely palliative.